June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Eyelid Sebaceous Carcinoma and Program cell death ligand 1 expression
Author Affiliations & Notes
  • Patricia Odashiro
    - Department of Pathology, Laval University, Quebec, CA, Quebec city, Quebec, Canada
    Ocular Pathology Laboratory, MUHC-McGill University, Montreal, Quebec, Canada
  • Alexandre Odashiro
    - Department of Pathology, Laval University, Quebec, CA, Quebec city, Quebec, Canada
    Ocular Pathology Laboratory, MUHC-McGill University, Montreal, Quebec, Canada
  • Ana Beatriz Toledo Dias
    Ocular Pathology Laboratory, MUHC-McGill University, Montreal, Quebec, Canada
  • Pablo Zoroquiain
    Ocular Pathology Laboratory, MUHC-McGill University, Montreal, Quebec, Canada
  • Denise Miyamoto
    Ocular Pathology Laboratory, MUHC-McGill University, Montreal, Quebec, Canada
  • Miguel N Burnier
    Ocular Pathology Laboratory, MUHC-McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Patricia Odashiro, None; Alexandre Odashiro, None; Ana Beatriz Dias, None; Pablo Zoroquiain, None; Denise Miyamoto, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3363. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Patricia Odashiro, Alexandre Odashiro, Ana Beatriz Toledo Dias, Pablo Zoroquiain, Denise Miyamoto, Miguel N Burnier; Eyelid Sebaceous Carcinoma and Program cell death ligand 1 expression. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3363.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Sebaceous Carcinoma (SC) is a very aggressive malignant tumor and represents the 2nd or 3rd most common malignant tumor of the eyelid. The expression of Programmed Death-1 ligand (PD-L1) by tumor cells is an effective mechanism to escape anti-tumor immunity. PD-1/PD-L1 blockade by monoclonal antibodies are emerging as an effective treatment option in multiple malignant tumors. There are currently no studies in the literature investigating the PD-L1 expression in SC.

Methods : Eighteen cases of formalin-fixed, paraffin-embedded eyelid SC were evaluated for PD-L1 expression by immunohistochemistry using the Ventana system. The slides were digitalized and the Aperio software for imaging analyzes was used. The percentage and intensity of the membranous cells staining was record.

Results : Nine (50%) out of 18 cases showed expression of PD-L1 ranging from 1% to 15% of the SC cells. In 2 (11%) of the positive cases, there were cells with strong or moderate complete membranous pattern of staining. The other 7 (39%) positive cases showed weak or incomplete membranous pattern of staining

Conclusions : Our data show that a half of the SC express PD-L1. This supports the relevance of more studies and clinical trials to test the efficacy of PD-1 inhibitors for the treatment of SC.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×